RxDoctor Payments Data

Charles Deck, MD

Internal Medicine · Scranton, PANPI 1982698866

Payments from drug & device makers

$156in general payments, 2019–2025

Across 10 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$59
  • Medtronic$19
  • Biohaven Pharmaceutical Holding Company Ltd.$17
  • GSK$16
  • AstraZeneca$15
  • Hologic Sales And Service, LLC$15
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$156100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$156 in reported general payments places this provider in the 50th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$63,971
Medicare patients
181
Services billed
812

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban137$73,263
OxycontinOxycodone Hcl38$45,103
JardianceEmpagliflozin45$40,996
XareltoRivaroxaban17$22,271
OzempicSemaglutide21$21,568
EntrestoSacubitril/Valsartan14$12,075
Spiriva RespimatTiotropium Bromide12$9,317
JanuviaSitagliptin Phosphate18$7,850
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,446
AbrysvoRsv Vacc, Pref A And Pref B/Pf22$7,029
ShingrixVaricella-Zoster Ge/As01b/Pf31$6,816
Fluticasone-SalmeterolFluticasone Propion/Salmeterol45$6,652
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$4,686
Novolog FlexpenInsulin Aspart19$3,764
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen118$2,409

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$59$21,56821 claims
GSKTrelegy Ellipta, Shingrix$16$14,26342 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Scranton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →